BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Eisai Company, Ltd. (ESALY.PK) Announces Appointment Of Vice President Of Sales & Marketing


10/19/2005 5:11:46 PM

TEANECK, N.J., Oct. 7 /PRNewswire/ -- Eisai Inc. today announces the immediate appointment of Frank Ciriello as Vice President of Sales & Marketing. In his role, Mr. Ciriello will be responsible for the development and execution of marketing and sales strategies to drive the profitable growth of Eisai's full pharmaceutical product line.

Mr. Ciriello joined Eisai from Aventis, where he served in various positions since 1985, prior to the formation of the Aventis organization. His most recent position was Vice President, Respiratory Franchise Head, Global Marketing and Medical.

Mr. Ciriello began his career with Marion Laboratories as a Field Sales Representative in New York City and subsequently held additional field positions as a Hospital Sales Representative and as a District Sales Manager, before moving into product management in 1993. Since then, he has held a number of progressively responsible positions in marketing and management that have spanned numerous therapeutic lines and across the various companies formed from subsequent merger activity.

"Mr. Ciriello brings a wealth of talent and experience in the pharmaceutical industry to Eisai," said Lonnel Coats, President & COO. "As we continue to expand our sales force in support of our leading treatments, Aricept(R) (donepezil hydrochloride tablets), Aciphex(R) (rabeprazole sodium tablets), and Zonegran(R) (zonisamide capsules), we are confident that Mr. Ciriello will play a key role in helping Eisai achieve its sales and growth goals."

About Eisai Inc.

Eisai Inc. is a US pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care company that discovers, develops, and markets products in more than 30 countries.

Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of more than $1.7 billion in fiscal year 2003 (year ending March 31, 2004).

Eisai Inc. employs approximately 1,100 people at its headquarters in Teaneck, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in its CNS, neurology, primary care and hospital field forces. Between 1998 and 2003, Eisai Inc. moved up rapidly in the rankings (based on revenues) of US pharmaceutical companies from No. 44 to No. 20.

For full prescribing information on Aricept(R), Aciphex(R) and Zonegran(R), visit http://www.eisai.com/ .

Eisai Inc.

CONTACT: Cathy Pollini of Eisai Inc., +1-201-287-2052, or Julia Lamm ofHill & Knowlton, +1-212-885-0413



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES